FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224254769> ?p ?o ?g. }

• W4224254769 endingPage "S150" @default.
• W4224254769 startingPage "S150" @default.
• W4224254769 abstract "Purpose Effector and regulatory T cells (Tregs) are main cell populations in the context of cardiac allograft vasculopathy (CAV). The immunostimulant plerixafor mobilizes hematopoietic stem cells and may boost T cells. Therefore, the aim of this study was to evaluate if a single, repeated, or continous treatment with plerixafor increases peripheral bone marrow derived stem cells including Tregs leading to tolerance induction and thus reducing chronic rejection in a mouse allograft transplant model. Methods Fully allogeneic mouse aortas from C57BL/6 mice (H2b) were abdominally transplanted into CBA mice (H2k). The continuously plerixafor application [1mg/kg/d] was carried for 14 days using implanted small osmotic pumps. Single dose (s.c.) injection of 1mg/kg/d or 5mg/kg/d were done at day 1 after transplantation (Tx.) and pulsed injections [1mg/kg/d] were conducted on days 1, 7, 14, and 21 after Tx. The control allograft group received vehicle loaded osmotic pumps. Stem cell mobilization was monitored by FACS. Recipients were sacrificed on day 14 for intragraft gene expression analysis or on day 30 for histological measurements. Results Murine aortic grafts with pulsed plerixafor injections showed significantly reduced neointima proliferation compared to control allografts (33.65%±8.84% vs.53.13% ±12.41%; p<0.05). The single shot and continuous treatment groups exhibited no improvement concerning neointima formation. First FACS analysis revealed significantly less hematopoietic stem cells (HSC) in the bone marrow of plerixafor treated mice vs. the control at day 14 after Tx. There were significantly more HSCs in the peripheral blood on day 30 after Tx, with the pulsed injection even doubling HSCs [0.0152%±0.008; p<0.005 (pulsed); 0.0046%±0.002%; p<0.01 (pump); 0.0076%±0.001%; p<0.01 (single dose 1mg/kg); 0.0039%±0.0017%; p<0.1 (single dose 5mg/kg) vs. 0.0018%±0.0016% (control)]. Preliminary intragraft gene expression results showed clearly reduced IFNγ expression and a significantly increase of IL-4, IL-10 and TGFβ. Conclusion These data suggest that both the continued and injected application of plerixafor leads to potent stem cell mobilization and hereby the repeated treatment with plerixafor reduces neointima formation in a mouse aortic transplant model. Further analysis are under progress. Effector and regulatory T cells (Tregs) are main cell populations in the context of cardiac allograft vasculopathy (CAV). The immunostimulant plerixafor mobilizes hematopoietic stem cells and may boost T cells. Therefore, the aim of this study was to evaluate if a single, repeated, or continous treatment with plerixafor increases peripheral bone marrow derived stem cells including Tregs leading to tolerance induction and thus reducing chronic rejection in a mouse allograft transplant model. Fully allogeneic mouse aortas from C57BL/6 mice (H2b) were abdominally transplanted into CBA mice (H2k). The continuously plerixafor application [1mg/kg/d] was carried for 14 days using implanted small osmotic pumps. Single dose (s.c.) injection of 1mg/kg/d or 5mg/kg/d were done at day 1 after transplantation (Tx.) and pulsed injections [1mg/kg/d] were conducted on days 1, 7, 14, and 21 after Tx. The control allograft group received vehicle loaded osmotic pumps. Stem cell mobilization was monitored by FACS. Recipients were sacrificed on day 14 for intragraft gene expression analysis or on day 30 for histological measurements. Murine aortic grafts with pulsed plerixafor injections showed significantly reduced neointima proliferation compared to control allografts (33.65%±8.84% vs.53.13% ±12.41%; p<0.05). The single shot and continuous treatment groups exhibited no improvement concerning neointima formation. First FACS analysis revealed significantly less hematopoietic stem cells (HSC) in the bone marrow of plerixafor treated mice vs. the control at day 14 after Tx. There were significantly more HSCs in the peripheral blood on day 30 after Tx, with the pulsed injection even doubling HSCs [0.0152%±0.008; p<0.005 (pulsed); 0.0046%±0.002%; p<0.01 (pump); 0.0076%±0.001%; p<0.01 (single dose 1mg/kg); 0.0039%±0.0017%; p<0.1 (single dose 5mg/kg) vs. 0.0018%±0.0016% (control)]. Preliminary intragraft gene expression results showed clearly reduced IFNγ expression and a significantly increase of IL-4, IL-10 and TGFβ. These data suggest that both the continued and injected application of plerixafor leads to potent stem cell mobilization and hereby the repeated treatment with plerixafor reduces neointima formation in a mouse aortic transplant model. Further analysis are under progress." @default.
• W4224254769 created "2022-04-26" @default.
• W4224254769 creator A5033753752 @default.
• W4224254769 creator A5040043499 @default.
• W4224254769 creator A5051024104 @default.
• W4224254769 creator A5068225703 @default.
• W4224254769 creator A5079174367 @default.
• W4224254769 creator A5091196503 @default.
• W4224254769 date "2022-04-01" @default.
• W4224254769 modified "2023-09-26" @default.
• W4224254769 title "Stem Cell Mobilization by Plerixafor Has an Affirmatory Effect on the Development of Transplant Vasculopathy in a Murine Aortic Allograft Model" @default.
• W4224254769 doi "https://doi.org/10.1016/j.healun.2022.01.354" @default.
• W4224254769 hasPublicationYear "2022" @default.
• W4224254769 type Work @default.
• W4224254769 citedByCount "0" @default.
• W4224254769 crossrefType "journal-article" @default.
• W4224254769 hasAuthorship W4224254769A5033753752 @default.
• W4224254769 hasAuthorship W4224254769A5040043499 @default.
• W4224254769 hasAuthorship W4224254769A5051024104 @default.
• W4224254769 hasAuthorship W4224254769A5068225703 @default.
• W4224254769 hasAuthorship W4224254769A5079174367 @default.
• W4224254769 hasAuthorship W4224254769A5091196503 @default.
• W4224254769 hasConcept C109159458 @default.
• W4224254769 hasConcept C126322002 @default.
• W4224254769 hasConcept C129470790 @default.
• W4224254769 hasConcept C13373296 @default.
• W4224254769 hasConcept C203014093 @default.
• W4224254769 hasConcept C2776914184 @default.
• W4224254769 hasConcept C2777339539 @default.
• W4224254769 hasConcept C2778283817 @default.
• W4224254769 hasConcept C2778583881 @default.
• W4224254769 hasConcept C2778828106 @default.
• W4224254769 hasConcept C2780007613 @default.
• W4224254769 hasConcept C28328180 @default.
• W4224254769 hasConcept C2911091166 @default.
• W4224254769 hasConcept C71924100 @default.
• W4224254769 hasConcept C86803240 @default.
• W4224254769 hasConcept C95444343 @default.
• W4224254769 hasConcept C98274493 @default.
• W4224254769 hasConceptScore W4224254769C109159458 @default.
• W4224254769 hasConceptScore W4224254769C126322002 @default.
• W4224254769 hasConceptScore W4224254769C129470790 @default.
• W4224254769 hasConceptScore W4224254769C13373296 @default.
• W4224254769 hasConceptScore W4224254769C203014093 @default.
• W4224254769 hasConceptScore W4224254769C2776914184 @default.
• W4224254769 hasConceptScore W4224254769C2777339539 @default.
• W4224254769 hasConceptScore W4224254769C2778283817 @default.
• W4224254769 hasConceptScore W4224254769C2778583881 @default.
• W4224254769 hasConceptScore W4224254769C2778828106 @default.
• W4224254769 hasConceptScore W4224254769C2780007613 @default.
• W4224254769 hasConceptScore W4224254769C28328180 @default.
• W4224254769 hasConceptScore W4224254769C2911091166 @default.
• W4224254769 hasConceptScore W4224254769C71924100 @default.
• W4224254769 hasConceptScore W4224254769C86803240 @default.
• W4224254769 hasConceptScore W4224254769C95444343 @default.
• W4224254769 hasConceptScore W4224254769C98274493 @default.
• W4224254769 hasIssue "4" @default.
• W4224254769 hasLocation W42242547691 @default.
• W4224254769 hasOpenAccess W4224254769 @default.
• W4224254769 hasPrimaryLocation W42242547691 @default.
• W4224254769 hasRelatedWork W1978598034 @default.
• W4224254769 hasRelatedWork W1989954717 @default.
• W4224254769 hasRelatedWork W2035629708 @default.
• W4224254769 hasRelatedWork W2038751426 @default.
• W4224254769 hasRelatedWork W2046259286 @default.
• W4224254769 hasRelatedWork W2162587612 @default.
• W4224254769 hasRelatedWork W2253242983 @default.
• W4224254769 hasRelatedWork W2314522894 @default.
• W4224254769 hasRelatedWork W2412102303 @default.
• W4224254769 hasRelatedWork W325523310 @default.
• W4224254769 hasVolume "41" @default.
• W4224254769 isParatext "false" @default.
• W4224254769 isRetracted "false" @default.
• W4224254769 workType "article" @default.